Open AccessSafety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial
Author(s) -
Satyendra Kumar Singh,
Sermili Rini Singnarpi
Publication year - 2021
Publication title -
indian journal of dermatology, venereology, and leprology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.514
H-Index - 45
eISSN - 0973-3922
pISSN - 0378-6323
DOI - 10.25259/ijdvl_613_19
Subject(s) - medicine , methotrexate , psoriasis , adverse effect , gastroenterology , psoriasis area and severity index , plaque psoriasis , pharmacology , dermatology
Background: Psoriasis is a chronic, inflammatory, relapsing and remitting disease with no cure till date. There is a paucity of trials using a combination of methotrexate (MTX) and cyclosporine (CsA) in chronic plaque psoriasis, due to fear of added toxicity, although they are time tested treatment options for monotherapy. Aims: The study aimed to compare the efficacy and adverse effect profile of the standard recommended dose of MTX (i.e. 0.3mg/kg/week) versus a combination of reduced doses of MTX and CsA (i.e. MTX 0.15 mg/kg/week with CsA 2.5mg/kg/day) in patients with chronic plaque psoriasis. Methods: Study design was a non-blinded randomised controlled trial. Patients of chronic plaque psoriasis with PASI more than 10 were randomised in 1: 1 allocation to receive either 0.3 mg/kg/week of intramuscular MTX injection or a combination of 0.15 mg/kg/week of intramuscular MTX injection and 2.5 mg/kg/day of CsA rounded off to the nearest 25 mg. Patients were followed up at every 2 weeks for 12 weeks. The doses were kept fixed throughout the study period. Results: A total of 66 patients received MTX monotherapy, whereas 67 patients received the combination. At baseline, both groups were comparable in their BSA ( P = 0.105, Student t-test) and PASI ( P = 0.277, Student t-test), which reduced significantly at 12 weeks in both groups ( P < 0.001, paired t-test). The achievement of PASI-75 ( P = 0.005), PASI-90 ( P < 0.001) and PASI-100 ( P = 0.001) was more in the combination group (Chi square test). Intention to treat analysis using Chi square test also showed better outcomes for PASI-75 ( P = 0.027), PASI-90 ( P < 0.001) and PASI-100 ( P = 0.001) in the combination group. Combination group also had earlier onset of action ( P = 0.001, Chi square test). There was no significant difference between the groups in terms of laboratory and clinical adverse events. Limitations: Non-blinded, no comparison with CsA monotherapy arm, no follow up beyond 12 weeks. Conclusion: The combination of reduced doses of MTX and CsA is more efficacious with earlier onset of action and similar adverse effects as with MTX monotherapy.